Update26 Nov 2014 09:58
(Thanks ArianParod HL) Upto 10 potential buyers MARKET REPORT: Buyers lining up for Sinclair sale as shares rise 12% to three-year highGEOFF FOSTER FOR THE DAILY MAILPUBLISHED: 015, 26 November 2014 | UPDATED: 015, 26 November 2014No less than ten interested parties are believed to have shown an interest in Sinclair IS Pharma, which has put itself up for sale.Shares of the aesthetics and skincare company rose 4p or 12 per cent to a three-year high of 36.5p after it was revealed it has appointed Rothschild to explore means of realising shareholder value. In other words, find a buyer.Private equity players and Swiss food giant Nestle, which earlier this year set up a specialised medical skin care division after acquiring the rights to sell certain products in the US and Canada from Valeant Pharmaceuticals for £840million cash, are rumoured to be heading the queue of buyers willing to pay up to about £300million or 60p-plus a share for the company, which owns an anti-ageing treatment that could turn out to be better than Botox.Promising: No less than ten interested parties are believed to have shown an interest in Sinclair IS Pharma, which has put itself up for saleIt was on the cards that Sinclair would be re-rated following the recent stonking £42billion bid for Botox giant Allergan.Sinclair owns Silhouette, a company which manufactures Silhouette Soft, a £1,200 anti-ageing treatment that uses dissolvable thread to beat wrinkles. Broker N+1 Singer is bullish and says the company’s exciting product portfolio could bring substantial value to a potential acquirer.Major Sinclair shareholders include heavyweights Toscafund, Lansdowne and George Soros. He lifted his stake above 5 per cent in June by acquiring more stock at 32p a pop.
Sign In
Follow the stocks
